Taffic

Description

Generic Name: Bictegravir + Emtricitabine + Tenofovir Alafenamide

Composition:
Each film coated tablet contains:
Bictegravir – 50 mg
Emtricitabine IP – 200 mg
Tenofovir Alafenamide – 25 mg

Indication:
TAFFIC –
It is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in
adults who have no antiretroviral treatment history or to replace the current antiretroviral
regimen in those who are virologically suppressed (HIV – 1 RNA less than 50 copies per ml) on a
stable antiretroviral regimen for at least 3 month with no history of treatment failure and no
known substitutions associated with resistance to Bictegravir, Emtricitabine and Tenofovir
Alafenamide.

Method of administration
• Oral use
• TAFFIC can be taken with or without food
• The film-coated tablets should not be chewed, crushed or split.

Contraindications
· Hypersensitivity to the active substances or to any of the excipients.
· Co-administration with rifampicin and St. John’s wort (Hypericum perforatum).
· Dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events.